Biggest News Aggregation in the World
📰 La 167 News

La 167 News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from La 167. Real-time updates on events, politics, business and more.

Kelun's Trop2 ADC meets primary endpoints in phase III triple-negative breast cancer trial

Kelun-Biotech Biopharmaceutical Co. Ltd.’s trophoblast cell-surface antigen 2 (Trop2)-targeted antibody-drug conjugate (ADC), SKB-264, met the primary endpoint of progression-free survival (PFS) in a phase III trial in patients with unresectable locally advanced, recurrent or metastatic triple-negative breast cancer (TNBC), according to an interim analysis.
Biotech Biopharmaceutical Co Kelun Biotech Biopharmaceutical Kelun Biotech Biopharmaceutical Co Ltd Antibody Drug Conjugates Skb 264 Metastatic Triple Negative Breast Cancer

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science